MCM10 promotes hepatocellular carcinoma progression through cyclin D1 regulation

Table 3 Stratified analysis on the association between MCM10⁺ Cyclin D1 expression and overall survival of hepatocellular carcinoma

Variables	All case	MCM10low and Cyclin D1low		MCM10high or Cyclin D1high		HR (95%CI)1	P value1
		Case number	MST (months)	Case number	MST (months)
Cases	147	48	100.0	99	53.0	2.426 (1.309-4.496)	0.005
Age (years)
≤ 50	76	31	89.0	45	53.0	1.838 (0.850-3.975)	0.122
> 50	71	17	110.0	54	55.0	4.167 (1.261-13.768)	0.019
Gender
Male	129	43	108.0	86	53.0	3.270 (1.579-6.771)	0.001
Female	18	5	27.0	13	45.0	0.474 (0.130-1.735)	0.260
HBsAg
Negative	30	10	62.5	20	34.5	1.647 (0.578-4.691)	0.350
Positive	117	38	106.5	79	55.0	2.932 (1.356-6.341)	0.006
ALT (U/L)
≤ 40	81	26	96.5	55	51.0	1.892 (0.919-3.894)	0.084
> 40	66	22	104.0	44	55.0	4.223 (1.238-14.401)	0.021
TBIL (μmol/L)
≤ 17.1	110	34	96.5	76	50.5	2.183 (1.083-4.401)	0.029
> 17.1	37	14	105.0	23	73.0	3.182 (0.864-11.722)	0.082
PT (s)
≤ 13.5	131	43	100.0	88	56.0	2.173 (1.138-4.150)	0.019
> 13.5	16	5	100.0	11	24.0	5.565 (0.664-46.619)	0.113
ALB (g/L)
≥ 35	137	46	96.5	91	57.0	2.083 (1.114-3.895)	0.022
< 35	10	2	116.0	8	10.0	58.055 (0.049-68429)	0.260
AFP (ng/mL)
≤ 200	93	35	100.0	58	72.0	1.495 (0.723-3.090)	0.278
> 200	54	13	110.0	41	36.0	6.531 (1.536-27.765)	0.011
Capsule integrity
Complete	66	24	100.0	42	91.5	1.211 (0.454-3.230)	0.701
No/incomplete	81	24	97.0	57	27.0	3.871 (1.693-8.852)	0.001
Tumor number
Single	105	38	106.5	67	72.0	1.954 (0.905-4.216)	0.088
Multiple (≥ 2)	42	10	69.0	32	27.5	2.841 (0.979-8.249)	0.055
Tumor differentiation
I-II	82	28	107.5	54	69.0	2.363 (0.951-5.873)	0.064
III-IV	65	20	87.0	45	36.0	2.373 (1.026-5.487)	0.043
Tumor size
≤ 5 cm	57	24	82.5	33	82.0	0.678 (0.261-1.760)	0.425
> 5 cm	90	24	110.0	66	35.0	5.575 (1.984-15.666)	0.001
T stage
T1-T2	106	43	100.0	63	76.0	1.518 (0.731-3.153)	0.263
T3-T4	41	5	100.0	36	19.0	3.776 (0.881-16.193)	0.074
Vascular invasion
No	106	41	100.0	65	67.0	2.059 (1.018-4.163)	0.044
Yes	41	7	110.0	34	26.0	2.875 (0.669-12.360)	0.156
BCLC stage
A-B	102	35	108.0	67	55.0	2.546 (1.155-5.609)	0.020
C	45	13	89.0	32	45.0	2.091 (0.779-5.613)	0.143

¹Hazard ratio and P value were derived from univariate analysis.

Bold values indicate significant P < 0.05. MST: Median survival time; HR: Hazard ratio; CI: Confidence interval; ALT: Alanine aminotransferase; TBil: Total bilirubin; PT: Prothrombin time; ALB: Albumin; AFP: Alpha-fetoprotein; HBsAg: Hepatitis B surface antigen.